ReviewTrends in molecular medicine2010
Therapeutic prospects for mitochondrial disease.
Review in Trends in molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Mitochondrial DNA Damage and Its Repair Mechanisms in Aging Oocytes.International journal of molecular sciences · 2024Review
- LONP-1 and ATFS-1 sustain deleterious heteroplasmy by promoting mtDNA replication in dysfunctional mitochondria.Nature cell biology · 2022Article
- Melatonin as a Potential Multitherapeutic Agent.Journal of personalized medicine · 2021Review
- Mitochondrial Proteome of Affected Glutamatergic Neurons in a Mouse Model of Leigh Syndrome.Frontiers in cell and developmental biology · 2020Article
- mRNA Reprogramming of T8993G Leigh's Syndrome Fibroblast Cells to Create Induced Pluripotent Stem Cell Models for Mitochondrial Disorders.Stem cells and development · 2019Article
- Emerging therapies for mitochondrial diseases.Essays in biochemistry · 2018Review
- Human mitochondrial nucleases.The FEBS journal · 2017Review
- Biochemical Assessment of Coenzyme QJournal of clinical medicine · 2017Review
- Genetic manipulation for inherited neurodegenerative diseases: myth or reality?The British journal of ophthalmology · 2016Review
- Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?Neuromolecular medicine · 2016Review
- Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.Mitochondrion · 2015Review
- Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies.Disease models & mechanisms · 2015Review
- Context-Dependent Role of Mitochondrial Fusion-Fission in Clonal Expansion of mtDNA Mutations.PLoS computational biology · 2015Article
- Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders.Nature communications · 2014Article
- The impact of mitochondrial function/dysfunction on IVF and new treatment possibilities for infertility.Reproductive biology and endocrinology : RB&E · 2014Review
- Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.Experimental brain research · 2014Article
- Invertebrate models for coenzyme q10 deficiency.Molecular syndromology · 2014Article
- Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells.Cell reports · 2014Article
- Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.British journal of pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Until even only a few years ago, the idea that effective therapies for human mitochondrial disorders resulting from the dysfunction of the respiratory chain/oxidative phosphorylation system (OxPhos) could be developed was unimaginable. The obstacles to treating diseases caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA), and which had the potential to affect nearly every organ system, seemed overwhelming. However, although clinically applicable therapies remain largely in the future, the landscape has changed dramatically and we can now envision the possibility of treating some of these disorders. Among these are techniques to upregulate mitochondrial biogenesis, enhance organellar fusion and fission, "shift heteroplasmy" and eliminate the burden of mutant mtDNAs via cytoplasmic transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.